Wan Gi Byun

Wan Gi Byun

Auto-generated profile, based on publicly available information

Wan Gi Byun

Department of Chemistry Seoul National University Seoul 08826 Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
HSHayoung Son
Hayoung Son
DKDahham Kim
Dahham Kim
SKSohee Kim
Sohee Kim
WBWan Gi Byun
Wan Gi Byun
Seung Bum ParkSeung Bum Park
Seung Bum Park

17 October 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
WBWan Gi Byun
Wan Gi Byun
MLMinha Lee
Minha Lee
MKMeehyun Ko
Meehyun Ko
JLJi Hyae Lee
Ji Hyae Lee
SYSihyeong Yi
Sihyeong Yi
Seung Bum ParkSeung Bum Park
Seung Bum Park
The ongoing global threats posed by COVID‐19 pandemic, catalyzed by SARS‐CoV‐2, underscores the pressing need for effective antiviral strategies. The viral non‐structural protein 1 (Nsp1) significantly influences pathogenicity by impeding host protein expression and enhancing viral RNA translation through its interaction with the stem‐loop 1 (SL1) in the 5′ untranslated region (UTR). We have developed a novel dual‐luciferase reporter assay, designed to investigate the critical Nsp1–SL1 interaction, and identified P23E02 as a potential inhibitor. Our investigation, combining molecular docking studies and alanine mutagenesis, has unveiled that P23E02 disrupts Nsp1–40S ribosomal subunit interaction, liberating translational inhibition and empowering host antiviral responses. P23E02 exhibits antiviral efficacy against various sarbecoviruses, making it a promising candidate for combatting COVID‐19 and related diseases. This study underscores the therapeutic potential of targeting the Nsp1/SL1 axis and lays the foundation for innovative antiviral interventions, ultimately fortifying global preparedness against future viral threats.

14 January 2026 in Advanced Science
Verified
Journal Article
Open access
WBWan Gi Byun
Wan Gi Byun
SSSumin Son
Sumin Son
JLJinAh Lee
JinAh Lee
MLMinha Lee
Minha Lee
MKMeehyun Ko
Meehyun Ko
Seung Bum ParkSeung Bum Park
Seung Bum Park
The increasing prevalence of emerging infectious diseases highlights the urgent need for broad‐spectrum antiviral therapeutics. Here, the discovery of SB2960, a small molecule, is reported that promotes stress granule (SG) formation and exhibits potent antiviral activity across diverse viral species. SB2960 suppresses viral replication with minimal cytotoxicity by modulating host antiviral immune responses. Target identification studies reveal that SB2960 engages receptor for activated protein C kinase 1 (RACK1), a key regulator of SG dynamics. Integrated transcriptomic and proteomic analyses further demonstrate that SB2960 alters the composition of SG and modulates the expression of antiviral genes. These findings establish SB2960 as a promising host‐directed broad‐spectrum antiviral agent and a valuable probe for investigating SG biology in the context of viral infection.

13 December 2024 in Angewandte Chemie
Verified
Journal Article
Closed access
HSHayoung Son
Hayoung Son
DKDahham Kim
Dahham Kim
SKSohee Kim
Sohee Kim
WBWan Gi Byun
Wan Gi Byun
Seung Bum ParkSeung Bum Park
Seung Bum Park

17 October 2024 in Angewandte Chemie
Verified
Journal Article
Open access
WBWan Gi Byun
Wan Gi Byun
MLMinha Lee
Minha Lee
MKMeehyun Ko
Meehyun Ko
JLJi Hyae Lee
Ji Hyae Lee
SYSihyeong Yi
Sihyeong Yi
Seung Bum ParkSeung Bum Park
Seung Bum Park
The ongoing global threats posed by COVID‐19 pandemic, catalyzed by SARS‐CoV‐2, underscores the pressing need for effective antiviral strategies. The viral non‐structural protein 1 (Nsp1) significantly influences pathogenicity by impeding host protein expression and enhancing viral RNA translation through its interaction with the stem‐loop 1 (SL1) in the 5′ untranslated region (UTR). We have developed a novel dual‐luciferase reporter assay, designed to investigate the critical Nsp1–SL1 interaction, and identified P23E02 as a potential inhibitor. Our investigation, combining molecular docking studies and alanine mutagenesis, has unveiled that P23E02 disrupts Nsp1–40S ribosomal subunit interaction, liberating translational inhibition and empowering host antiviral responses. P23E02 exhibits antiviral efficacy against various sarbecoviruses, making it a promising candidate for combatting COVID‐19 and related diseases. This study underscores the therapeutic potential of targeting the Nsp1/SL1 axis and lays the foundation for innovative antiviral interventions, ultimately fortifying global preparedness against future viral threats.